# Variantyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/variantyx

- Industry: Biotechnology
- Headquarters: Framingham, US
- Website: www.variantyx.com
- Total disclosed funding: $99M
- Latest round: Series D (Apr 1, 2024)
- Investors on record: 8

## About

Established in 2014 by Haim Neerman and Tomer Jackman, and based in Massachusetts, US, Variantyx, Inc. is a medical firm that offers diagnostics for the treatment of rare genetic illnesses, reproductive genetics, and oncology therapy optimization. In April 2024, Variantyx, Inc. raised USD 36 million in venture funding from Peregrine Ventures, Pitango Venture Capital, New Era Capital Partners, and Robert Bosch Venture Capital.

Variantyx provides advanced molecular diagnostic solutions using whole genome sequencing. The firm’s offerings include diagnostic testing for rare genetic disorders, reproductive genetics, tumor profiling in oncology through OncoAlly™, wellness testing for general health, and genomic profiling for pharmaceutical research. The platform integrates multiple types of genetic data to deliver comprehensive insights from a single sample, aiding in accurate diagnosis and treatment optimization.

The company intends to use the April 2024 funding to finance further commercial and technological development.

## Funding rounds

- Series D, Apr 1, 2024, $36M — Pitango, Peregrine Ventures, Robert Bosch Venture Capital, New Era Capital Partners
- Series C, Feb 12, 2022, $42M — Pitango, Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, New Era Capital Partners
- Series C, Nov 15, 2021, $6M — Robert Bosch Venture Capital
- Series C, Feb 18, 2021, $16M — Pitango, IBM Ventures, 20/20 HealthCare Partners, GF Securities, Quark Venture, New Era Capital Partners

## Investors

- Pitango (https://capitalatlas.ai/funds/pitango) — Series C, Series D
- IBM Ventures (https://capitalatlas.ai/funds/ibm-ventures) — Series C
- 20/20 HealthCare Partners (https://capitalatlas.ai/funds/20-20-healthcare-partners) — Series C
- GF Securities — Series C
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series C
- New Era Capital Partners (https://capitalatlas.ai/funds/new-era-capital-partners) — Series C, Series D
- Robert Bosch Venture Capital (https://capitalatlas.ai/funds/robert-bosch-venture-capital) — Series C, Series D
- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series C, Series D